Omnicell (OMCL) 10-Q 6 Nov 15 2015 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2015	Oct. 29, 2015
Entity [Abstract]
Entity Registrant Name	OMNICELL, Inc
Entity Central Index Key	926,326
Document Type	10-Q
Document Period End Date	Sep. 30, 2015
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		35,427,994
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q3

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 57,757	$ 125,888
Accounts receivable, net of allowances of $1,733 and $1,279, respectively	115,680	82,763
Inventories	49,460	31,554
Prepaid expenses	17,698	23,518
Deferred tax assets	12,489	12,446
Other current assets	6,802	7,215
Total current assets	259,886	283,384
Property and equipment, net	34,026	36,178
Long-term net investment in sales-type leases	13,557	10,848
Goodwill	148,727	122,720
Intangible assets, net	92,042	82,667
Long-term deferred tax assets	1,513	1,144
Other long-term assets	26,971	23,273
Total assets	576,722	560,214
Current liabilities:
Accounts payable	24,691	19,432
Accrued compensation	15,224	19,874
Accrued liabilities	29,382	19,299
Deferred service revenue	26,168	25,167
Deferred gross profit	27,179	28,558
Total current liabilities	122,644	112,330
Deferred service revenue, long-term	18,436	20,308
Long-term deferred tax liabilities	32,320	30,454
Other long-term liabilities	11,782	7,024
Total liabilities	$ 185,182	$ 170,116
Commitments and contingencies
Stockholders’ equity:
Common stock, $0.001 par value, 100,000 shares authorized; 44,548 and 43,540 shares issued; 35,403 and 35,816 shares outstanding, respectively	$ 45	$ 43
Treasury stock, at cost, 9,145 and 7,721 shares outstanding	(185,074)	(135,053)
Additional paid-in capital	485,919	457,436
Retained earnings	92,138	69,033
Accumulated other comprehensive income (loss)	(1,488)	(1,361)
Total stockholders’ equity	391,540	390,098
Total liabilities and stockholders’ equity	$ 576,722	$ 560,214

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets Parenthetical - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Allowances	$ 1,733	$ 1,279
Common Stock, Par Value (in dollars per share)	$ 0.001	$ 0.001
Common Stock, Shares, Authorized	100,000,000	100,000,000
Common Stock, Shares, Issued	44,548,000	43,540,000
Common Stock, Shares, Outstanding	35,403,000	35,816,000
Treasury Stock, Shares	9,145,000	7,721,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Revenues:
Product	$ 100,941	$ 92,229	$ 284,204	$ 260,053
Services and other revenues	24,293	20,314	70,039	59,306
Total revenues	125,234	112,543	354,243	319,359
Cost of revenues:
Cost of product revenues	51,700	44,510	143,319	124,413
Cost of services and other revenues	9,831	8,487	28,074	24,865
Total cost of revenues	61,531	52,997	171,393	149,278
Gross profit	63,703	59,546	182,850	170,081
Operating expenses:
Research and development	9,176	7,078	25,941	19,670
Selling, general and administrative	40,668	38,871	123,690	114,302
Gain on business combination	0	0	(3,443)	0
Total operating expenses	49,844	45,949	146,188	133,972
Income from operations	13,859	13,597	36,662	36,109
Other income (expense), net	(646)	(706)	(1,635)	(1,003)
Income before provision for income taxes	13,213	12,891	35,027	35,106
Provision for income taxes	5,177	5,591	11,922	13,824
Net income	$ 8,036	$ 7,300	$ 23,105	$ 21,282
Net income per share:
Basic (in dollars per share)	$ 0.22	$ 0.20	$ 0.64	$ 0.60
Diluted (in dollars per share)	$ 0.22	$ 0.20	$ 0.63	$ 0.58
Weighted-average shares outstanding:
Basic (in shares)	35,806	35,994	35,983	35,634
Diluted (in shares)	36,613	36,832	36,870	36,617

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Statement of Comprehensive Income [Abstract]
Net income	$ 8,036	$ 7,300	$ 23,105	$ 21,282
Other comprehensive loss, net of reclassification adjustments:
Foreign currency translation adjustments	(1,555)	(669)	(127)	(550)
Other comprehensive loss	(1,555)	(669)	(127)	(550)
Comprehensive income	$ 6,481	$ 6,631	$ 22,978	$ 20,732

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Operating Activities
Net income	$ 23,105	$ 21,282
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	18,457	14,705
Loss on disposal of fixed assets	114	221
Gain on business combination	(3,443)	0
Provision for receivable allowance	542	850
Share-based compensation expense	11,267	8,610
Income tax benefits from employee stock plans	3,838	4,065
Excess tax benefits from employee stock plans	(3,942)	(4,456)
Provision for excess and obsolete inventories	317	450
Deferred income taxes	(2,235)	1,307
Changes in operating assets and liabilities:
Accounts receivable, net	(26,132)	(35,028)
Inventories	(13,215)	1,301
Prepaid expenses	5,937	1,015
Other current assets	1,019	1,412
Net investment in sales-type leases	(3,220)	677
Other long-term assets	247	360
Accounts payable	(127)	5,420
Accrued compensation	(5,003)	(6,533)
Accrued liabilities	4,608	(416)
Deferred service revenue	(4,199)	2,650
Deferred gross profit	(1,170)	15,585
Other long-term liabilities	(833)	838
Net cash provided by operating activities	5,932	34,315
Investing Activities
Acquisition of intangible assets, intellectual property and patents	(331)	(236)
Software development for external use	(9,445)	(7,925)
Purchases of property and equipment	(6,081)	(10,151)
Business acquisitions, net of cash acquired	(25,455)	(19,749)
Net cash used in investing activities	(41,312)	(38,061)
Financing Activities
Proceeds from issuances under stock-based compensation plans	15,665	18,157
Employees' taxes paid related to restricted stock units	(2,285)	(2,023)
Common stock repurchases	(50,021)	(17,052)
Excess tax benefits from employee stock plans	3,942	4,456
Net cash (used) provided by financing activities	(32,699)	3,538
Effect of exchange rate changes on cash and cash equivalents	(52)	(136)
Net decrease in cash and cash equivalents	(68,131)	(344)
Cash and cash equivalents at beginning of period	125,888	104,531
Cash and cash equivalents at end of period	57,757	104,187
Supplemental cash flow information
Cash paid for interest	94	0
Cash paid for taxes, net of refunds	7,027	0
Supplemental disclosing of non-cash investing activities
Unpaid property and equipment purchases	554	444
Non-cash activity business acquisition	7,386	860
Treasury stock in accrued liabilities	$ 0	$ 2,586

Organization and Summary of Sig

Organization and Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Organization and Summary of Significant Accounting Policies	Organization and Summary of Significant Accounting Policies Business Omnicell, Inc. was incorporated in California in 1992 under the name Omnicell Technologies, Inc. and reincorporated in Delaware in 2001 as Omnicell, Inc. Our major products are automated medication, supply control systems and medication adherence solutions which are sold in our principal market, which is the healthcare industry. Our market is primarily located in the United States and Canada. "Omnicell," "our," "us," "we," or the "Company" collectively refer to Omnicell, Inc. and its subsidiaries. Basis of presentation The accompanying unaudited Condensed Consolidated Financial Statements reflect, in the opinion of management, all adjustments, consisting of normal recurring adjustments and accruals, necessary to present fairly the financial position of the Company as of September 30, 2015 and December 31, 2014 , the results of their operations, comprehensive income and cash flows for the three and nine months ended September 30, 2015 and September 30, 2014 . Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) have been condensed or omitted in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”). These unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and accompanying Notes included in our annual report on Form 10-K for the year ended December 31, 2014 filed with the SEC on March 30, 2015. Our results of operations, comprehensive income and cash flows for the three and nine months ended September 30, 2015 are not necessarily indicative of results that may be expected for the year ending December 31, 2015 , or for any future period. Principles of consolidation The Condensed Consolidated Financial Statements include the accounts of the Company and its subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. On April 21, 2015, we completed the acquisition of Mach4 Automatisierungstechnik GmbH (“Mach4”), a privately held German limited liability company with registered office in Bochum, Germany. On April 30, 2015, we acquired the remaining 85% of the issued and outstanding ordinary shares of Avantec Healthcare Limited (“Avantec”) not already held by Omnicell. The consolidated financial statements include the results of operations of Mach4 and Avantec commencing as of their respective acquisition dates. Use of estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our Condensed Consolidated Financial Statements and accompanying Notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management's best knowledge of current events and actions that may impact the Company in the future, actual results may be different from the estimates. Our critical accounting policies are those that affect our financial statements materially and involve difficult, subjective or complex judgments by management. Those policies are revenue recognition, share-based compensation, inventory valuation, accounts receivable and notes receivable (net investment in sales-type leases), valuation of goodwill, purchased intangibles and long-lived assets, and accounting for income taxes. Segment reporting change As previously disclosed, since the first quarter of 2015, we modified the segment presentation to reflect the changes in how our Chief Operating Decision Maker (“CODM”) reviews the segments and the overall business. See Note 14, Segment Information, for additional information on our segment reporting change. Our CODM is our Chief Executive Officer. With the increase in completed acquisitions in the last two years , our CODM changed how the financial information was reviewed to exclude general corporate-level costs that are not specific to either of the reporting segments when evaluating the operating results of each segment. Corporate-level costs include expenses related to executive management, finance and accounting, human resources, legal, training and development, and certain administrative expenses. The historical information presented has been retrospectively adjusted to reflect the modified segment reporting. Our CODM allocates resources and evaluates the performance of our segments using information about its revenues, gross profit and income from operations, excluding certain costs which are managed separately at the corporate level. We enhanced our segment reporting structure to match our operating structure based on how our CODM views the business and allocates resources, beginning in the first quarter of 2015. Concentration of credit risk Financial instruments that may potentially subject us to concentrations of credit risk consist principally of cash equivalents and accounts receivable. Cash equivalents are maintained with several financial institutions and may exceed the amount of insurance provided on such balances. The majority of our accounts receivable are derived from sales to customers for commercial applications. We perform ongoing credit evaluations of our customers’ financial condition and limit the amount of credit extended when deemed necessary but generally require no collateral. We maintain reserves for potential credit losses. Our products are broadly distributed and there were no customers that accounted for more than 10% of our accounts receivable as of September 30, 2015 and December 31, 2014 . We believe that we have no significant concentrations of credit risk as of September 30, 2015 . Significant accounting policies There have been no material changes in our significant accounting policies for the three and nine months ended September 30, 2015 , as compared to the significant accounting policies described in our annual report on Form 10-K for the year ended December 31, 2014 . Recently issued authoritative guidance In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update ("ASU") No. 2014-09, Revenue from Contracts with Customers. Under the new guidance, an entity is required to recognize an amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The original effective date for the ASU would have required the Company to adopt the standard beginning in its first quarter of fiscal year 2017. In July 2015, the FASB voted to amend ASU No. 2014-09 by approving a one-year deferral of the effective date as well as providing the option to early adopt the standard on the original effective date. Accordingly, we may adopt the standard in its first quarter of fiscal year 2018. The new revenue guidance may be applied retrospectively to each prior period presented or retrospectively with the cumulative effect recognized as of the date of adoption. We are currently evaluating the impact of the adoption of this accounting standard update on our consolidated financial position or results of operations. In July 2015, the FASB issued ASU No. 2015-11, Simplifying the Measurement of Inventory. The new guidance changes the measurement principle for inventory from the lower of cost or market to lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. It applies to entities that measure inventory using a method other than last-in, first-out (LIFO) and the retail inventory method (RIM). The new guidance will be effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years and should be applied prospectively. Early adoption is permitted as of the beginning of an interim or annual reporting period. We are currently evaluating the impact of the adoption of this accounting standard update on our consolidated financial position or results of operations. In September 2015, the FASB issued ASU No. 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments. This ASU requires adjustments to provisional amounts that are identified during the measurement period of a business combination to be recognized in the reporting period in which the adjustment amounts are determined. Acquirers are no longer required to revise comparative information for prior periods as if the accounting for the business combination had been completed as of the acquisition date. The provisions of ASU 2015-16 are effective for reporting periods beginning after December 15, 2015. We are currently evaluating the impact of the adoption of this accounting standard update on our consolidated financial position or results of operations. There was no other recently issued authoritative guidance that has a material impact on our Condensed Consolidated Financial Statements through the reporting date.

Net Income Per Share

Net Income Per Share	9 Months Ended
	Sep. 30, 2015
Earnings Per Share [Abstract]
Net Income Per Share	Net Income Per Share Basic net income per share is computed by dividing net income for the period by the weighted-average number of shares outstanding during the period. Diluted net income per share is computed by dividing net income for the period by the weighted-average number of shares, less shares repurchased, plus, if dilutive, potential common stock outstanding during the period. Potential common stock includes the effect of outstanding dilutive stock options, restricted stock awards and restricted stock units computed using the treasury stock method. The anti-dilutive weighted-average dilutive shares related to stock award plans are excluded from the computation of the diluted net income per share because their effect would have been anti-dilutive. The calculation of basic and diluted net income per share is as follows: Three months ended September 30, Nine months ended September 30, 2015 2014 2015 2014 (In thousands, except per share data) Net income $ 8,036 $ 7,300 $ 23,105 $ 21,282 Weighted-average shares outstanding — basic 35,806 35,994 35,983 35,634 Dilutive effect of employee stock plans 807 838 887 983 Weighted-average shares outstanding — diluted 36,613 36,832 36,870 36,617 Net income per share — basic $ 0.22 $ 0.20 $ 0.64 $ 0.60 Net income per share — diluted $ 0.22 $ 0.20 $ 0.63 $ 0.58 Anti-dilutive weighted-average shares related to stock award plans 478 427 380 364

Cash and Cash Equivalents and F

Cash and Cash Equivalents and Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Cash and Cash Equivalents and Fair Value of Financial Instruments	Cash and Cash Equivalents and Fair Value of Financial Instruments Cash and cash equivalents as of September 30, 2015 and December 31, 2014 includes cash and money market funds, which have original maturities of three months or less. Due to the short duration to maturity, the carrying value of such financial instruments approximates the estimated fair value. The cash and cash equivalents at September 30, 2015 and December 31, 2014 were as follows: September 30, December 31, (In thousands) Cash $ 17,649 $ 61,311 Money market fund 40,108 64,577 Total cash and cash equivalents $ 57,757 $ 125,888 Fair value hierarchy The Company measures its financial instruments at fair value. The Company’s cash equivalents are classified within Level 1 of the fair value hierarchy as they are valued primarily using quoted market prices utilizing market observable inputs. The Company's foreign currency contracts are classified within Level 2 as the valuation inputs are based on quoted prices and market observable data of similar instruments. The Level 3 valuation inputs include the Company’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. The inputs are unobservable in the market and significant to the instrument’s valuation. The following table represents the fair value hierarchy of the Company’s financial assets measured at fair value as of September 30, 2015 : Level 1 Level 2 Level 3 Total (In thousands) Money market funds $ 40,108 $ — $ — $ 40,108 Derivative contracts — 17 — 17 Total financial assets $ 40,108 $ 17 $ — $ 40,125 Contingent consideration liability — — 5,572 5,572 Total financial Liabilities $ — $ — $ 5,572 $ 5,572 The significant unobservable inputs used in the fair value measurement of the contingent consideration classified as level 3 above are the achievement of booking targets and the discount rate. We did not hold any Level 3 assets or liabilities as of December 31, 2014. There have been no transfers between fair value measurement levels during the three and nine months ended September 30, 2015 and September 30, 2014. The following table represents the fair value hierarchy of the Company’s financial asset measured at fair value as of December 31, 2014 : Level 1 Level 2 Total (In thousands) Money market fund $ 64,577 $ — $ 64,577 Total financial assets $ 64,577 $ — $ 64,577 The Company had no financial liabilities measured at fair value at December 31, 2014 . Net investment in sales-type leases. The carrying amount of our sales-type lease receivables is a reasonable estimate of fair value as the unearned interest income is immaterial. Foreign Currency Risk Management We operate in foreign countries, which exposes us to market risk associated with foreign currency exchange rate fluctuations between the U.S. dollar and various foreign currencies, the most significant of which is the British Pound and Euro. In order to manage foreign currency risk, we enter into foreign exchange forward contracts to mitigate risks associated with changes in spot exchange rates of mainly non-functional currency denominated assets or liabilities of our foreign subsidiaries. In general, the market risk related to these contracts is offset by corresponding gains and losses on the hedged transactions. By working only with major banks and closely monitoring current market conditions, we seek to limit the risk that counterparties to these contracts may be unable to perform. The foreign exchange forward contracts are measured at fair value and reported as other current assets or accrued liabilities on the Condensed Consolidated Balance Sheets. The derivative instruments we use to hedge this exposure are not designated as hedges. Any gains or losses on the foreign exchange forward contracts are recognized in earnings as Other Income/Expense in the period incurred in the Condensed Consolidated Statements of Operations. We do not enter into derivative contracts for trading purposes. The aggregate notional amounts of our outstanding foreign exchange contracts as of September 30, 2015 were $1.8 million . The aggregate fair value of these outstanding foreign exchange contracts as of September 30, 2015 were less than $0.1 million . We did not have any outstanding foreign exchange contracts as of December 31, 2014.

Balance Sheet Components

Balance Sheet Components	9 Months Ended
	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Balance Sheet Components	Balance Sheet Components September 30, December 31, (In thousands) Inventories: Raw materials $ 11,027 $ 8,254 Work in process 2,238 64 Finished goods 36,195 23,236 Total inventories $ 49,460 $ 31,554 Property and equipment: Equipment $ 44,448 $ 42,829 Furniture and fixtures 5,903 5,689 Leasehold improvements 9,064 8,701 Purchased software 29,770 28,920 Construction in progress 4,902 1,538 Property and equipment, gross 94,087 87,677 Accumulated depreciation and amortization (60,061 ) (51,499 ) Total property and equipment, net $ 34,026 $ 36,178 Other long term assets: Capitalized software, net $ 24,838 $ 19,643 Other assets 2,133 3,630 Total other long term assets, net $ 26,971 $ 23,273 Accrued liabilities: Rebates and lease buyouts $ 4,603 $ 6,512 Advance payments from customers 7,567 4,834 Group purchasing organization fees 3,437 3,475 Taxes payable 3,574 2,181 Other accrued liabilities 10,201 2,297 Total accrued liabilities $ 29,382 $ 19,299

Net Investment in Sales-Type Le

Net Investment in Sales-Type Leases	9 Months Ended
	Sep. 30, 2015
Leases [Abstract]
Net Investment in Sales-Type Leases	Net Investment in Sales-Type Leases On recurring basis, we enter into sales-type lease transactions which vary in length from one to five years. The receivables as a result of these type of transactions are collateralized by the underlying equipment leased and consist of the following components at September 30, 2015 and December 31, 2014: September 30, December 31, (In thousands) Net minimum lease payments to be received $ 20,731 $ 17,616 Less: unearned interest income portion (1,000 ) (1,131 ) Net investment in sales-type leases 19,731 16,485 Less: short-term portion* (6,174 ) (5,637 ) Long-term net investment in sales-type leases $ 13,557 $ 10,848 * The short-term portion of the net investments in sales-type leases are included in the Other current assets on the Condensed Consolidated Balance Sheets. We evaluate our sales-type leases individually and collectively for impairment, and recorded $0.1 million collective allowance for credit losses as of September 30, 2015 and $0.2 million as of December 31, 2014 . At September 30, 2015 , the future minimum lease payments under sales-type leases are as follows: September 30, Year ended December 31, (In thousands) Remaining three months of 2015 $ 1,774 2016 6,454 2017 5,428 2018 3,808 2019 2,188 Thereafter 1,079 Total $ 20,731

Business Acquisitions

Business Acquisitions	9 Months Ended
	Sep. 30, 2015
Business Combinations [Abstract]
Business Acquisitions	Business Acquisitions Mach4 Acquisition On April 21, 2015, we completed the acquisition of Mach4, a privately held German limited liability company with its registered office in Bochum, Germany pursuant to a share purchase agreement (the “Mach4 Agreement”), under which Omnicell International, Inc., a wholly-owned subsidiary of Omnicell Inc., purchased the entire issued share capital of Mach4 (the “Mach4 Acquisition”). Mach4 manufactures robotic dispensing systems used by retail and hospital pharmacies and the Mach4 acquisition provides Omnicell with a more robust product offering that is intended to be leveraged to create opportunities to sell additional Omnicell medication cabinets. The robotic storage and dispensing product offering provides Omnicell with a solution to better compete for international market share. Pursuant to the terms of the Mach4 Agreement, we paid approximately $17.2 million in cash after adjustments provided for in the Mach4 Agreement, of which $2.7 million was placed in an escrow fund, which will be distributed to Mach4's former stockholders subject to claims that we may make against the escrow fund with respect to indemnification and other claims within 18 months after the closing date of this transaction. Avantec Acquisition On April 30, 2015, we completed the acquisition of Avantec, the privately-held distributor of Omnicell’s products in the United Kingdom, pursuant to a share purchase agreement (the “Avantec Agreement”). Pursuant to the Avantec Agreement, we acquired the remaining 85% of issued and outstanding ordinary shares of Avantec that was not previously owned by the Company. Avantec develops medication and supply automation products that complement our solutions for configurations suited to the United Kingdom marketplace, and had been the exclusive distributor of our medication and supply automation solutions since 2005 in the United Kingdom. Pursuant to the terms of the Avantec Agreement, we agreed to pay $12.0 million in cash (the “Purchase Consideration”) and potential earn-out payments of up to $3.0 million payable after December 31, 2015 and an additional $3.0 million payable after December 31, 2016, based on future bookings. The fair value of these potential earn-out payments as of the acquisition date was $5.6 million . Pursuant to the terms of the Avantec Agreement we retained $1.8 million of the Purchase Consideration to be held to settle any future indemnification claims within 18 months period that we may make following the closing. The fair value of the contingent consideration liability related to Avantec is revalued at each reporting date or more frequently if circumstances dictate. Changes in the fair value of this obligation are recorded as income or expense within other expense in our condensed consolidated statements of operation. The significant unobservable inputs used in the fair value measurement of the contingent consideration are the achievement of booking targets and the discount rate. Significant increases or decreases in any of those inputs in isolation would result in a significantly lower or higher fair value measurement. Prior to the Avantec Acquisition, we accounted for our 15% ownership interest in Avantec as an equity-method investment. The Avantec acquisition -date carrying book value of our previous equity interest was $1.3 million . This transaction was accounted for as a step acquisition, which required us to re-measure our previously held 15% ownership interest to fair value and record the difference between the fair value and carrying value as a gain. The fair value of the equity investment was determined to be $4.7 million which resulted in a gain of $3.4 million that was recorded in operating income in our Condensed Consolidated Statement of Operations in the three months ended June 30, 2015. Both of the above acquired companies are included in our Automation and Analytics segment. We accounted for the transactions above under the provisions of FASB Accounting Standards Codification ("ASC") Topic 805, Business Combinations . Accordingly, the estimated fair value of the consideration transferred to purchase the acquired companies is allocated to the assets acquired and the liabilities assumed based on their respective fair values. We have made significant estimates and assumptions in determining the allocation of the acquisition consideration. The purchase price allocations are subject to certain post-closing working capital adjustments for the acquired current assets and current liabilities of both acquisitions at their respective acquisition dates. The total consideration and the allocation of consideration to the individual net assets is preliminary, as there are remaining uncertainties to be resolved, including the settlement of the final net working capital adjustment for each. Our preliminary allocation of the total purchase price for each transaction is summarized below: Mach4 Avantec Total (In thousands) Cash $ 397 $ 3,392 $ 3,789 Accounts receivable 3,743 3,607 7,350 Inventory 3,580 1,428 5,008 Deferred tax assets and other current assets 368 89 457 Total current assets 8,088 8,516 16,604 Property and equipment 463 — 463 Intangibles 7,710 6,341 14,051 Goodwill 10,539 15,606 26,145 Other non-current assets 52 — 52 Total assets 26,852 30,463 57,315 Current liabilities 3,684 4,125 7,809 Non-current deferred tax liabilities 2,564 1,269 3,833 Deferred service revenue and gross profit 2,314 928 3,242 Other non-current liabilities 1,056 — 1,056 Total purchase price $ 17,234 $ 24,141 $ 41,375 Total purchase price, net of cash received $ 16,837 $ 20,749 $ 37,586 Identifiable intangible assets Intangible assets acquired and their respective estimated remaining useful lives over which each asset will be amortized are as follows: Mach4 Avantec Fair value Weighted Fair value Weighted average useful life (In thousands) (In years) (In thousands) (In years) Developed technology $ 3,290 8 $ — — Trade name 850 6 92 2 Customer relationships 3,570 11-12 5,834 12 Backlog — — 415 2 Total purchased intangible assets $ 7,710 $ 6,341 Developed technology represents completed technology that has reached the technological feasibility and/or is currently offered for sale to Mach4 customers. The fair value is determined based on the relief from royalty method under the income approach, which requires us to estimate a reasonable royalty rate, identify relevant projected revenues and expenses, and select an appropriate discount rate. A royalty rate of 5.0% was used to value the developed technology. The after-tax cash flows were discounted to present value utilizing a 17.5% discount rate, which is based on our company-wide required return for this acquisition plus a discount of 1.5% to account for the unique riskiness of the asset. The developed technology had a fair value of $3.3 million and had an estimated economic life of eight years based on estimated technological obsolescence and is being amortized on an accelerated basis. Trade name represents the fair value brand recognition that was determined using the relief-from-royalty method under the income approach. A royalty rate of 1.0% and 2.0% was used to value the trade names of Avantec and Mach4, respectively. The value of trade names of $0.1 million for Avantec is being amortized on straight-line method and $0.9 million for Mach4 is being amortized on an accelerated basis. Customer relationships represent the fair value of future projected revenues that will be derived from the sale of products to existing customers of the acquired company. The fair value of the customer relationships is determined based on the excess earnings method under the income approach that resulted in a value of $3.6 million for Mach4 and $5.8 million for Avantec and has been amortized over their useful lives on accelerated basis. Backlog represents the fair value of sales order backlog as of the valuation date and its fair value is determined based on the excess earnings method under the income approach and is being amortized on straight-line method. Goodwill The goodwill arising from these acquisitions is primarily attributed to sales of future products and services and the assembled workforce. Goodwill is not deductible for tax purposes. Goodwill is not being amortized but is reviewed annually for impairment or more frequently if impairment indicators arise, in accordance with authoritative guidance. The following table presents certain unaudited pro forma information for illustrative purposes only, for fiscal 2015 and fiscal 2014 as if Mach4 and Avantec had been acquired on January 1, 2014. The unaudited estimated pro forma information combines the historical results of Mach4 and Avantec with our consolidated historical results and includes certain adjustments reflecting the estimated impact of fair value adjustments for the respective periods. The pro forma information is not indicative of what would have occurred had the acquisitions taken place on January 1, 2014. Additionally, the pro forma financial information does not include the impact of possible business model changes between Mach4, Avantec and the Company. We expect to achieve further business synergies, as a result of the acquisitions that are not reflected in the pro forma amounts that follow. As a result, actual results will differ from the unaudited pro forma information presented (in thousands, except per share data): Nine months ended September 30, 2015 2014 (In thousands, except per share data) Pro forma net revenues $ 361,217 $ 340,915 Pro forma net income $ 23,742 $ 22,511 Pro forma net income per share basic $ 0.66 $ 0.63 Pro forma net income per share diluted $ 0.64 $ 0.61

Goodwill and Intangible Assets

Goodwill and Intangible Assets	9 Months Ended
	Sep. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Goodwill and Intangible Assets Goodwill The following table represents changes in the carrying amount of goodwill: Automation and Analytics Medication Adherence Total (In thousands) Net balance as of December 31, 2014 $ 28,543 $ 94,177 $ 122,720 Goodwill acquired - Mach4 10,539 — 10,539 Goodwill acquired - Avantec 15,606 — 15,606 Foreign currency exchange rate fluctuations 194 (332 ) (138 ) Net balance as of September 30, 2015 $ 54,882 $ 93,845 $ 148,727 Intangible assets, net The carrying amounts of intangibles as of September 30, 2015 are as follows: September 30, 2015 Gross carrying amount Accumulated amortization Foreign currency exchange rate fluctuations Net carrying amount Useful life (years) (In thousands, except for years) Customer relationships $ 69,520 $ (10,317 ) $ (355 ) $ 58,848 5 - 30 Acquired technology 30,991 (5,534 ) 14 25,471 3 - 20 Trade names 8,069 (2,289 ) (6 ) 5,774 1 - 12 Patents 1,986 (342 ) — 1,644 2 - 20 Backlog 424 (105 ) (14 ) 305 1.7 Total intangibles assets, net $ 110,990 $ (18,587 ) $ (361 ) $ 92,042 The carrying amounts of intangibles as of December 31, 2014 were as follows: December 31, 2014 Gross carrying amount Accumulated amortization Foreign currency exchange rate fluctuations Net carrying amount Useful life (years) Customer relationships $ 60,150 $ (7,596 ) $ (323 ) $ 52,231 5 - 30 Acquired technology 27,580 (4,068 ) — 23,512 3 - 20 Trade names 7,110 (1,559 ) (17 ) 5,534 3 - 12 Patents 1,655 (265 ) — 1,390 2 - 20 Total intangibles assets, net $ 96,495 $ (13,488 ) $ (340 ) $ 82,667 Amortization expense of intangible assets was $2.0 million and $1.2 million for the three months ended September 30, 2015 and September 30, 2014 , respectively, and $5.1 million and $3.3 million for the nine months ended September 30, 2015 and September 30, 2014 , respectively. The estimated future amortization expenses for intangible assets are as follows: September 30, Year ended December 31, (In thousands) Remaining three months of 2015 $ 1,919 2016 6,849 2017 6,034 2018 5,546 2019 5,262 Thereafter 66,432 Total $ 92,042

Deferred Gross Profit

Deferred Gross Profit	9 Months Ended
	Sep. 30, 2015
Revenue Recognition [Abstract]
Deferred Gross Profit	Deferred Gross Profit Deferred gross profit consists of the following: September 30, December 31, (In thousands) Sales of medication and supply dispensing systems including packaging equipment (1) $ 44,158 $ 36,947 Less: cost of revenues, excluding installation costs (16,979 ) (8,389 ) Total deferred gross profit $ 27,179 $ 28,558 _________________________________________________ (1) Delivered and invoiced, pending installation.

Commitments

Commitments	9 Months Ended
	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments	Commitments Lease commitments We lease office space and office equipment under operating leases. At September 30, 2015, future minimum lease payments under such operating leases were as follows: September 30, (In thousands) Remaining three months of 2015 $ 1,751 2016 6,526 2017 5,885 2018 5,490 2019 5,481 Thereafter 15,216 Total minimum future lease payments $ 40,349 Purchase obligations During the course of the business, we issue purchase orders based on our current manufacturing needs. At September 30, 2015 , we had non-cancelable purchase commitments of $28.8 million , which are expected to be paid within the next twelve months.

Contingencies

Contingencies	9 Months Ended
	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Contingencies Legal Proceedings We are currently involved in various legal proceedings. As required under ASC 450, Contingencies , we accrue for contingencies when we believe that a loss is probable and that we can reasonably estimate the amount of any such loss. We have not recorded any accrual for contingent liabilities associated with the legal proceedings described below based on our belief that any potential loss, while reasonably possible, is not probable. Further, any possible range of loss in these matters cannot be reasonably estimated at this time. We believe that we have valid defenses with respect to legal proceedings pending against us. However, litigation is inherently unpredictable, and it is possible that cash flows or results of operations could be materially affected in any particular period by the unfavorable resolution of this contingency or because of the diversion of management's attention and the creation of significant expenses. Pending legal proceedings as of September 30, 2015 are as follows: On September 12, 2014, MV Circuit Design, Inc., an Ohio company ("MV Circuit"), brought an action to correct the inventorship of certain patents owned by Omnicell, as well as related state-law claims against Omnicell in the Northern District of Ohio (Case No. 1:14-cv-02028-DAP) regarding allegations of fraud in the filing and prosecution of U.S. Patent Nos. 8,180,485, 8,773,270, 8,812,153, PCT/US2007/003765, PCT/US2011/063597, and PCT/US2011/0635505 (the “Action”). On November 14, 2014, we filed a Motion to Dismiss the Action. MV Circuit responded on January 29, 2015, and we replied in support of our Motion to Dismiss on February 17, 2015. On March 24, 2015, the Court issued an Order granting in part and denying in part the Motion to Dismiss. Specifically, the Court granted Omnicell's Motion to Dismiss with respect to Counts 4, 5, and 6 (declaratory judgments regarding PCT/US2007/003765, PCT/US2011/063597, and PCT/US2011/0635505) and count 13 (civil conspiracy). The Court denied the Company's Motion to Dismiss with respect to Count 9 (fraud), Count 7 (fraudulent concealment) and Count 8 (negligent misrepresentation). Omnicell filed an Answer to the Complaint on April 8, 2015. Following an initial Case Management Conference on April 22, 2015, the Court ordered MV Circuit and Omnicell to make a limited initial production of documents. The parties completed this initial document production and held further conference calls with the Court on September 16 and October 19, 2015 to discuss a potential settlement. The parties are continuing settlement negotiations and a follow-up teleconference with the Court is scheduled for November 18, 2015. No case schedule has been set.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2015
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes We provide for income taxes for each interim period based on the estimated annual effective tax rate for the year, adjusting for discrete items in the quarter in which they arise. The annual effective tax rate before discrete items was 39.3% and 40.5% for the nine months ended September 30, 2015 and September 30, 2014 , respectively. The nine months ended September 30, 2015 and 2014 annual effective tax rate differed from the statutory rate of 35.0% primarily due to the unfavorable impact of state income taxes, non-deductible equity charges, and other non-deductible expenditures, which were partially offset by the domestic production activities deduction. We recorded a gain of $3.4 million attributable to the increase in the fair value of Omnicell's 15% minority interest in Avantec which was revalued in conjunction with our purchase of the remaining 85% of Avantec shares. This gain was treated as a discrete item and excluded from profit-before-tax in calculating the annual effective tax rate for the nine months ended September 30, 2015 . The federal research and development credit law, which was extended through December 31, 2014, retroactively has not been extended to the end of 2015. As a result the annual effect tax rate for the nine months ended September 30, 2015 and 2014 did not consider the effect of the federal research and development tax credit. As of September 30, 2015 and December 31, 2014, the Company had gross unrecognized tax benefits of $7.1 million and $5.9 million , respectively. It is the Company’s policy to classify accrued interest and penalties as part of the unrecognized tax benefits, but to record interest and penalties in operating expense. As of September 30, 2015 and December 31, 2014, the amount of accrued interest and penalties was immaterial. A s of September 30, 2015 , the calendar years 2011 and thereafter are open and are subject to potential examination in one or more jurisdictions. However, because all of the net operating loss and research credit carryforwards that may be used in future years are subject to adjustment, if and when utilized, our federal and California tax years remain open from 1996 and 1992, respectively. We have been contacted for audit by the Internal Revenue Service for tax years 2011, 2012 and 2013. Although we believe we have adequately provided for uncertain tax positions, the provisions on these positions may change as revised estimates are made or the underlying matters are settled or otherwise resolved. It is not possible at this time to reasonably estimate changes in the unrecognized tax benefits within the next twelve months.

Stock Repurchases

Stock Repurchases	9 Months Ended
	Sep. 30, 2015
Equity [Abstract]
Stock Repurchases	Stock Repurchases In August 2012, our Board of Directors authorized a program (the "2012 Stock Repurchase Program") to repurchase up to $50.0 million of common stock, of which approximately $45.1 million had been repurchased as of December 31, 2014, and the remaining $4.9 million has been repurchased as of the second quarter of 2015 and the 2012 Stock Repurchase Program was concluded. In November 2014, our Board of Directors authorized a program (the "2014 Stock Repurchase Program") to repurchase up to $50.0 million of common stock of which approximately $45.1 million had been repurchased as of September 30, 2015 . The 2014 Stock Repurchase Program has a total of $4.9 million remaining for future repurchases as of September 30, 2015 , and the program has no expiration date. During the nine months ended September 30, 2015 , we repurchased approximately 1,424 thousand shares under our stock repurchase programs. The following table summarizes our stock repurchases: September 30, December 31, (In thousands, except per share data) Total number of shares repurchased 1,424 884 Dollar amount of shares repurchased $ 50,020 $ 24,091 Average price paid per share $ 35.13 $ 27.24

Employee Benefits and Share-Bas

Employee Benefits and Share-Based Compensation	9 Months Ended
	Sep. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Employee Benefits and Share-Based Compensation	Employee Benefits and Share-Based Compensation Stock based plans For a detailed explanation of our stock plans and subsequent changes please refer to Note 16, Employee Benefits and Stock-Based Compensation, of our Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on March 30, 2015. Share-based compensation expense The following table sets forth the total share-based compensation expense recognized in our Condensed Consolidated Statements of Operations: Three months ended Nine months ended September 30, September 30, September 30, September 30, (In thousands) Cost of product and service revenues $ 581 $ 441 $ 1,630 $ 973 Research and development 587 407 1,472 1,156 Selling, general and administrative 2,798 2,313 8,165 6,481 Total share-based compensation expense $ 3,966 $ 3,161 $ 11,267 $ 8,610 The following weighted average assumptions are used to value share options and Employee Stock Purchase Plan ("ESPP") shares issued pursuant to our equity incentive plans for the three and nine months ended September 30, 2015 and September 30, 2014 : Three months ended Nine months ended September 30, September 30, September 30, September 30, (In thousands, except percentages) Stock Option Plans Expected life, years 5.04 4.81 5.04 4.80 Expected volatility, % 29.3 % 34.1 % 31.1 % 35.1 % Risk free interest rate, % 1.73 % 1.70 % 1.63 % 1.56 % Estimated forfeiture rate % 2.5 % 2.5 % 2.5 % 2.5 % Dividend yield, % — % — % — % — % Three months ended Nine months ended September 30, September 30, September 30, September 30, (In thousands, except percentages) Employee Stock Purchase Plan Expected life, years 0.5-2.0 0.5-2.0 0.5-2.0 0.5-2.0 Expected volatility, % 25.79-34.36% 29.56-39.69% 25.79-37.53% 29.56-42.16% Risk free interest rate, % 0.12-0.79% 0.03-0.53% 0.03-0.79% 0.03-0.53% Estimated forfeiture rate % — % — % — % — % Dividend yield, % — % — % — % — % Stock option and restricted stock activity Stock options activity The following table summarizes the stock option activity under the Company’s equity incentive plans during the nine months ended September 30, 2015 : Number of Shares Weighted-Average Exercise Price Weighted-Average Remaining Years Aggregate Intrinsic Value (1) (In thousands, except per share data) Stock Options Outstanding at December 31, 2014 2,672 $ 19.02 6.5 Granted 322 34.90 Exercised (494 ) 15.90 Expired (2 ) 15.72 Forfeited (81 ) 23.82 Outstanding at September 30, 2015 2,417 $ 21.61 6.5 $ 24,341 Exercisable at September 30, 2015 1,368 $ 16.73 4.8 $ 19,660 Vested and expected to vest at September 30, 2015 and thereafter 2,390 $ 21.50 6.4 $ 24,293 _________________________________________________ (1) Intrinsic value is calculated as the difference between the market value or closing price of our common stock as of the last trading day of the period as reported by the NASDAQ Global Select Market, and the exercise price of the option. The weighted-average fair value per share of options granted during the three and nine months ended September 30, 2015 , was $10.51 and $10.57 , respectively, and the weighted-average fair value per share of options granted during the three and nine months ended September 30, 2014 was $8.51 and $8.78 , respectively. The intrinsic value of options exercised during the three and nine months ended September 30, 2015 was $3.1 million and $9.7 million , respectively. The intrinsic value of options exercised during the three and nine months ended September 30, 2014 was $2.5 million and $10.4 million , respectively. As of September 30, 2015 , total unrecognized compensation cost related to unvested stock options was $9.0 million , which is expected to be recognized over a weighted-average vesting period of 2.7 years. Restricted stock activity Restricted stock activity under the Company’s equity incentive plans in the nine months ended September 30, 2015 is as follows: Number of Shares Weighted-Average Grant Date Fair Value Weighted-Average Remaining Years Aggregate Intrinsic Value (In thousands, except per share data) Restricted Stock Units (RSUs) Outstanding at December 31, 2014 399 $ 24.00 1.5 Granted 131 34.72 Vested (99 ) 21.51 Forfeited (29 ) 23.79 Outstanding and unvested at September 30, 2015 402 $ 28.10 1.3 $ 12,503 Expected to vest after September 30, 2015 392 1.2 $ 12,181 The weighted-average grant date fair value per share of RSUs granted during the nine months ended September 30, 2015 and September 30, 2014 was $34.72 and and $25.16 , respectively. As of September 30, 2015 , total unrecognized compensation expense related to RSUs was $9.3 million , which is expected to be recognized over the remaining weighted-average vesting period of 2.4 years . Number of Shares Weighted-Average Grant Date Fair Value (In thousands, except per share data) Restricted Stock Awards (RSAs) Outstanding at December 31, 2014 36 $ 26.47 Granted 37 36.05 Vested (41 ) 26.47 Forfeited (1 ) 27.65 Outstanding and unvested at September 30, 2015 31 $ 35.95 The weighted-average grant date fair value per share of RSAs granted during the nine months ended September 30, 2015 was and $36.05 . As of September 30, 2015 , total unrecognized compensation cost related to RSAs was $0.7 million , which is expected to be recognized over the remaining weighted-average vesting period of 0.7 years . Performance-based restricted stock unit activity Performance-based restricted stock activity under our equity incentive plans in the nine months ended September 30, 2015 is as follows: Number of Shares Weighted-Average Grant Date Fair Value Per Unit (In thousands, except per share data) Performance-based Restricted Stock Units (PSUs) Outstanding at December 31, 2014 233 $ 17.96 Granted 60 29.56 Vested (70 ) 18.91 Forfeited (27 ) 14.69 Outstanding and unvested at September 30, 2015 196 $ 21.63 The weighted-average grant date fair value per share of PSUs granted during the nine months ended September 30, 2015 and September 30, 2014 was $29.56 and $14.36 , respectively. The total fair value of PSUs that vested during the nine months ended September 30, 2015 and September 30, 2014 was $2.6 million and $2.1 million , respectively. As of September 30, 2015 , total unrecognized compensation cost related to PSUs was approximately $2.0 million , which is expected to be recognized over the remaining weighted-average period of 1.1 years . Employee Stock Purchase Plan (ESPP) activity The unrecognized compensation cost related to the shares to be purchased under our ESPP was approximately $2.1 million as of September 30, 2015 , and is expected to be recognized over a weighted-average period of 0.1 years . Summary of shares reserved for future issuance under equity incentive plans We had the following ordinary shares reserved for future issuance under our equity incentive plans as of June 30, 2015: Number of Shares (In thousands) Share options outstanding 2,417 Restricted share awards outstanding 629 Shares authorized for future issuance 4,402 ESPP shares available for future issuance 3,251 Total shares reserved for future issuance as of September 30, 2015 10,699

Segment Information

Segment Information	9 Months Ended
	Sep. 30, 2015
Segment Reporting [Abstract]
Segment Information	Segment Information In the first quarter of 2015, we modified the segment presentation to reflect the changes in how our Chief Operating Decision Maker (“CODM”) reviews the segments and the overall business. With the increase in completed acquisitions in the last two years , we changed how the financial information was presented for CODM review to exclude general corporate-level costs that are not specific to either of the reporting segments when evaluating the operating results of each segment. Corporate-level costs include expenses related to executive management, finance and accounting, human resources, legal, training and development, and certain administrative expenses. The historical information presented has been retrospectively adjusted to reflect the modified segment reporting. Our CODM allocates resources and evaluates the performance of our segments using information about its revenues, gross profit and income from operations, excluding certain costs which are managed separately at the corporate level. We enhanced our segment reporting structure to match our operating structure based on how our Chief Operating Decision Maker (“CODM”) views the business and allocates resources, beginning in the first quarter of 2015. Our CODM is our Chief Executive Officer. Retrospective adjustments of prior period financial information have been made to conform to the current period presentation. The two operating segments, which are the same as our reportable segments, are as follows: Automation and Analytics The Automation and Analytics segment is organized around the design, manufacturing, selling and servicing of medication and supply dispensing systems, pharmacy inventory management systems, and related software. Our Automation and Analytics products are designed to enable our customers to enhance and improve the effectiveness of the medication-use process, the efficiency of the medical-surgical supply chain, overall patient care and clinical and financial outcomes of medical facilities. Through modular configuration and upgrades, our systems can be tailored to specific customer needs. Medication Adherence The Medication Adherence segment includes primarily the manufacturing and selling of consumable medication blister cards, packaging equipment and ancillary products and services. These products are used to manage medication administration outside of the hospital setting and include medication adherence products sold under the brand name MTS Medication Technologies ("MTS"), Surgichem Limited ("Surgichem"), and under the Omnicell and SureMed brands. MTS products consist of proprietary medication packaging systems and related products for use by institutional pharmacies servicing long-term care, and correctional facilities or retail pharmacies serving patients in their local communities. The following table summarizes the financial performance of our reportable segments, including a reconciliation of income from segment operations to income from total operations: Three Months Ended September 30, 2015 September 30, 2014 Automation and Analytics Medication Adherence Total Automation and Analytics Medication Adherence Total (In thousands) Revenues $ 102,967 $ 22,267 $ 125,234 $ 89,547 $ 22,996 $ 112,543 Cost of revenues 45,668 15,863 61,531 38,412 14,585 52,997 Gross profit 57,299 6,404 63,703 51,135 8,411 59,546 Operating expenses 30,628 6,070 36,698 27,420 4,822 32,242 Income from segment operations $ 26,671 $ 334 $ 27,005 $ 23,715 $ 3,589 $ 27,304 Corporate costs 13,146 13,707 Income from operations $ 13,859 $ 13,597 Nine Months Ended September 30, 2015 September 30, 2014 Automation and Analytics Medication Adherence Total Automation and Analytics Medication Adherence Total (In thousands) Revenues $ 284,447 $ 69,796 $ 354,243 $ 255,748 $ 63,611 $ 319,359 Cost of revenues 123,923 47,470 171,393 109,344 39,934 149,278 Gross profit 160,524 22,326 182,850 146,404 23,677 170,081 Operating expenses 85,195 18,321 103,516 78,566 14,273 92,839 Income from segment operations $ 75,329 $ 4,005 $ 79,334 $ 67,838 $ 9,404 $ 77,242 Corporate costs 42,672 41,133 Income from operations $ 36,662 $ 36,109 _________________________________________________ Significant customers There were no customers that accounted for more than 10% of our total revenues for the three and nine months ended September 30, 2015 and three and nine months ended September 30, 2014 .

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2015
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events On October 29, 2015, we entered into a securities purchase agreement (the “Securities Purchase Agreement”) with Aesynt Holding, L.P., Aesynt, Ltd. (together with Aesynt Holding, L.P., the “Sellers”) and Aesynt Coöperatief U.A. (“Aesynt”). Pursuant to the terms and conditions of the Securities Purchase Agreement, we will acquire from the Sellers, and the Sellers will sell to Omnicell, all of the outstanding interests of Aesynt on the closing date (such acquisition, the “Aesynt Acquisition”). Aesynt is a provider of automated medication management systems, including dispensing robots with storage solutions, medication storage and dispensing carts and cabinets, IV sterile preparation robotics and software, including software related to medication management. The contemplated total aggregate consideration is $275.0 million , in cash, plus cash on hand at signing minus indebtedness at close, or approximately $217.5 million , subject to certain adjustments at closing as provided for in the Securities Purchase Agreement. The closing of the acquisition is subject to certain closing conditions, including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvement Act ("HSR") of 1976, as amended. In connection with the Securities Purchase Agreement, we entered into a commitment letter with Wells Fargo Bank, National Association (“Wells Fargo Bank”) and Wells Fargo Securities, LLC (“Wells Fargo Securities” and, together with Wells Fargo Bank, the “Commitment Parties”) on October 29, 2015, pursuant to which Wells Fargo Bank has committed to provide $300.0 million of senior secured credit facilities consisting of (a) a $200.0 million term loan facility, and (b) a $100.0 million revolving credit facility (collectively, the “Senior Credit Facilities”), a portion of which, together with our existing cash on hand, would be used to (i) refinance the loans under our existing senior secured credit facility, if any, and Aesynt’s existing senior secured credit facility, (ii) pay the purchase price for the Aesynt Acquisition, and (iii) pay any fees and expenses incurred in connection with any of the foregoing. The commitment to provide the loans under the Senior Credit Facilities is subject to certain conditions, including the negotiation of definitive documentation for the Senior Credit Facilities and other customary closing conditions.

Organization and Summary of S22

Organization and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Basis of presentation	Basis of presentation The accompanying unaudited Condensed Consolidated Financial Statements reflect, in the opinion of management, all adjustments, consisting of normal recurring adjustments and accruals, necessary to present fairly the financial position of the Company as of September 30, 2015 and December 31, 2014 , the results of their operations, comprehensive income and cash flows for the three and nine months ended September 30, 2015 and September 30, 2014 . Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) have been condensed or omitted in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”). These unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and accompanying Notes included in our annual report on Form 10-K for the year ended December 31, 2014 filed with the SEC on March 30, 2015. Our results of operations, comprehensive income and cash flows for the three and nine months ended September 30, 2015 are not necessarily indicative of results that may be expected for the year ending December 31, 2015 , or for any future period.
Principles of consolidation	Principles of consolidation The Condensed Consolidated Financial Statements include the accounts of the Company and its subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. On April 21, 2015, we completed the acquisition of Mach4 Automatisierungstechnik GmbH (“Mach4”), a privately held German limited liability company with registered office in Bochum, Germany. On April 30, 2015, we acquired the remaining 85% of the issued and outstanding ordinary shares of Avantec Healthcare Limited (“Avantec”) not already held by Omnicell. The consolidated financial statements include the results of operations of Mach4 and Avantec commencing as of their respective acquisition dates.
Use of estimates	Use of estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our Condensed Consolidated Financial Statements and accompanying Notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management's best knowledge of current events and actions that may impact the Company in the future, actual results may be different from the estimates. Our critical accounting policies are those that affect our financial statements materially and involve difficult, subjective or complex judgments by management. Those policies are revenue recognition, share-based compensation, inventory valuation, accounts receivable and notes receivable (net investment in sales-type leases), valuation of goodwill, purchased intangibles and long-lived assets, and accounting for income taxes.
Segment reporting change	Segment reporting change As previously disclosed, since the first quarter of 2015, we modified the segment presentation to reflect the changes in how our Chief Operating Decision Maker (“CODM”) reviews the segments and the overall business. See Note 14, Segment Information, for additional information on our segment reporting change. Our CODM is our Chief Executive Officer. With the increase in completed acquisitions in the last two years , our CODM changed how the financial information was reviewed to exclude general corporate-level costs that are not specific to either of the reporting segments when evaluating the operating results of each segment. Corporate-level costs include expenses related to executive management, finance and accounting, human resources, legal, training and development, and certain administrative expenses. The historical information presented has been retrospectively adjusted to reflect the modified segment reporting. Our CODM allocates resources and evaluates the performance of our segments using information about its revenues, gross profit and income from operations, excluding certain costs which are managed separately at the corporate level. We enhanced our segment reporting structure to match our operating structure based on how our CODM views the business and allocates resources, beginning in the first quarter of 2015.
Concentration of credit risk	Concentration of credit risk Financial instruments that may potentially subject us to concentrations of credit risk consist principally of cash equivalents and accounts receivable. Cash equivalents are maintained with several financial institutions and may exceed the amount of insurance provided on such balances. The majority of our accounts receivable are derived from sales to customers for commercial applications. We perform ongoing credit evaluations of our customers’ financial condition and limit the amount of credit extended when deemed necessary but generally require no collateral. We maintain reserves for potential credit losses. Our products are broadly distributed and there were no customers that accounted for more than 10% of our accounts receivable as of September 30, 2015 and December 31, 2014 . We believe that we have no significant concentrations of credit risk as of September 30, 2015 .
Recently issued authoritative guidance	Recently issued authoritative guidance In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update ("ASU") No. 2014-09, Revenue from Contracts with Customers. Under the new guidance, an entity is required to recognize an amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The original effective date for the ASU would have required the Company to adopt the standard beginning in its first quarter of fiscal year 2017. In July 2015, the FASB voted to amend ASU No. 2014-09 by approving a one-year deferral of the effective date as well as providing the option to early adopt the standard on the original effective date. Accordingly, we may adopt the standard in its first quarter of fiscal year 2018. The new revenue guidance may be applied retrospectively to each prior period presented or retrospectively with the cumulative effect recognized as of the date of adoption. We are currently evaluating the impact of the adoption of this accounting standard update on our consolidated financial position or results of operations. In July 2015, the FASB issued ASU No. 2015-11, Simplifying the Measurement of Inventory. The new guidance changes the measurement principle for inventory from the lower of cost or market to lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. It applies to entities that measure inventory using a method other than last-in, first-out (LIFO) and the retail inventory method (RIM). The new guidance will be effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years and should be applied prospectively. Early adoption is permitted as of the beginning of an interim or annual reporting period. We are currently evaluating the impact of the adoption of this accounting standard update on our consolidated financial position or results of operations. In September 2015, the FASB issued ASU No. 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments. This ASU requires adjustments to provisional amounts that are identified during the measurement period of a business combination to be recognized in the reporting period in which the adjustment amounts are determined. Acquirers are no longer required to revise comparative information for prior periods as if the accounting for the business combination had been completed as of the acquisition date. The provisions of ASU 2015-16 are effective for reporting periods beginning after December 15, 2015. We are currently evaluating the impact of the adoption of this accounting standard update on our consolidated financial position or results of operations. There was no other recently issued authoritative guidance that has a material impact on our Condensed Consolidated Financial Statements through the reporting date.

Net Income Per Share (Tables)

Net Income Per Share (Tables)	9 Months Ended
	Sep. 30, 2015
Earnings Per Share [Abstract]
Basic and Diluted Net Income Per Share	The calculation of basic and diluted net income per share is as follows: Three months ended September 30, Nine months ended September 30, 2015 2014 2015 2014 (In thousands, except per share data) Net income $ 8,036 $ 7,300 $ 23,105 $ 21,282 Weighted-average shares outstanding — basic 35,806 35,994 35,983 35,634 Dilutive effect of employee stock plans 807 838 887 983 Weighted-average shares outstanding — diluted 36,613 36,832 36,870 36,617 Net income per share — basic $ 0.22 $ 0.20 $ 0.64 $ 0.60 Net income per share — diluted $ 0.22 $ 0.20 $ 0.63 $ 0.58 Anti-dilutive weighted-average shares related to stock award plans 478 427 380 364

Cash and Cash Equivalents and24

Cash and Cash Equivalents and Fair Value of Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Assets Measured at Fair Value On A Recurring Basis	The cash and cash equivalents at September 30, 2015 and December 31, 2014 were as follows: September 30, December 31, (In thousands) Cash $ 17,649 $ 61,311 Money market fund 40,108 64,577 Total cash and cash equivalents $ 57,757 $ 125,888
Schedule of Financial Assets Measured At Fair Value	The following table represents the fair value hierarchy of the Company’s financial assets measured at fair value as of September 30, 2015 : Level 1 Level 2 Level 3 Total (In thousands) Money market funds $ 40,108 $ — $ — $ 40,108 Derivative contracts — 17 — 17 Total financial assets $ 40,108 $ 17 $ — $ 40,125 Contingent consideration liability — — 5,572 5,572 Total financial Liabilities $ — $ — $ 5,572 $ 5,572 The significant unobservable inputs used in the fair value measurement of the contingent consideration classified as level 3 above are the achievement of booking targets and the discount rate. We did not hold any Level 3 assets or liabilities as of December 31, 2014. There have been no transfers between fair value measurement levels during the three and nine months ended September 30, 2015 and September 30, 2014. The following table represents the fair value hierarchy of the Company’s financial asset measured at fair value as of December 31, 2014 : Level 1 Level 2 Total (In thousands) Money market fund $ 64,577 $ — $ 64,577 Total financial assets $ 64,577 $ — $ 64,577

Balance Sheet Components (Table

Balance Sheet Components (Tables)	9 Months Ended
	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Condensed Balance Sheet	September 30, December 31, (In thousands) Inventories: Raw materials $ 11,027 $ 8,254 Work in process 2,238 64 Finished goods 36,195 23,236 Total inventories $ 49,460 $ 31,554 Property and equipment: Equipment $ 44,448 $ 42,829 Furniture and fixtures 5,903 5,689 Leasehold improvements 9,064 8,701 Purchased software 29,770 28,920 Construction in progress 4,902 1,538 Property and equipment, gross 94,087 87,677 Accumulated depreciation and amortization (60,061 ) (51,499 ) Total property and equipment, net $ 34,026 $ 36,178 Other long term assets: Capitalized software, net $ 24,838 $ 19,643 Other assets 2,133 3,630 Total other long term assets, net $ 26,971 $ 23,273 Accrued liabilities: Rebates and lease buyouts $ 4,603 $ 6,512 Advance payments from customers 7,567 4,834 Group purchasing organization fees 3,437 3,475 Taxes payable 3,574 2,181 Other accrued liabilities 10,201 2,297 Total accrued liabilities $ 29,382 $ 19,299

Net Investment in Sales-Type 26

Net Investment in Sales-Type Leases (Tables)	9 Months Ended
	Sep. 30, 2015
Leases [Abstract]
Schedule of Long Term Net Investment in Sale-Type Leases	The receivables as a result of these type of transactions are collateralized by the underlying equipment leased and consist of the following components at September 30, 2015 and December 31, 2014: September 30, December 31, (In thousands) Net minimum lease payments to be received $ 20,731 $ 17,616 Less: unearned interest income portion (1,000 ) (1,131 ) Net investment in sales-type leases 19,731 16,485 Less: short-term portion* (6,174 ) (5,637 ) Long-term net investment in sales-type leases $ 13,557 $ 10,848 * The short-term portion of the net investments in sales-type leases are included in the Other current assets on the Condensed Consolidated Balance Sheets.
Schedule of Net Sale-Type Leases Minimum Lease Receivables	At September 30, 2015 , the future minimum lease payments under sales-type leases are as follows: September 30, Year ended December 31, (In thousands) Remaining three months of 2015 $ 1,774 2016 6,454 2017 5,428 2018 3,808 2019 2,188 Thereafter 1,079 Total $ 20,731

Business Acquisitions (Tables)

Business Acquisitions (Tables)	9 Months Ended
	Sep. 30, 2015
Business Combinations [Abstract]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed and Weighted Average Useful Life	Our preliminary allocation of the total purchase price for each transaction is summarized below: Mach4 Avantec Total (In thousands) Cash $ 397 $ 3,392 $ 3,789 Accounts receivable 3,743 3,607 7,350 Inventory 3,580 1,428 5,008 Deferred tax assets and other current assets 368 89 457 Total current assets 8,088 8,516 16,604 Property and equipment 463 — 463 Intangibles 7,710 6,341 14,051 Goodwill 10,539 15,606 26,145 Other non-current assets 52 — 52 Total assets 26,852 30,463 57,315 Current liabilities 3,684 4,125 7,809 Non-current deferred tax liabilities 2,564 1,269 3,833 Deferred service revenue and gross profit 2,314 928 3,242 Other non-current liabilities 1,056 — 1,056 Total purchase price $ 17,234 $ 24,141 $ 41,375 Total purchase price, net of cash received $ 16,837 $ 20,749 $ 37,586 Intangible assets acquired and their respective estimated remaining useful lives over which each asset will be amortized are as follows: Mach4 Avantec Fair value Weighted Fair value Weighted average useful life (In thousands) (In years) (In thousands) (In years) Developed technology $ 3,290 8 $ — — Trade name 850 6 92 2 Customer relationships 3,570 11-12 5,834 12 Backlog — — 415 2 Total purchased intangible assets $ 7,710 $ 6,341
Pro Forma Information	As a result, actual results will differ from the unaudited pro forma information presented (in thousands, except per share data): Nine months ended September 30, 2015 2014 (In thousands, except per share data) Pro forma net revenues $ 361,217 $ 340,915 Pro forma net income $ 23,742 $ 22,511 Pro forma net income per share basic $ 0.66 $ 0.63 Pro forma net income per share diluted $ 0.64 $ 0.61

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Carrying Amount of Goodwill	The following table represents changes in the carrying amount of goodwill: Automation and Analytics Medication Adherence Total (In thousands) Net balance as of December 31, 2014 $ 28,543 $ 94,177 $ 122,720 Goodwill acquired - Mach4 10,539 — 10,539 Goodwill acquired - Avantec 15,606 — 15,606 Foreign currency exchange rate fluctuations 194 (332 ) (138 ) Net balance as of September 30, 2015 $ 54,882 $ 93,845 $ 148,727
Intangible Assets, Net	The carrying amounts of intangibles as of September 30, 2015 are as follows: September 30, 2015 Gross carrying amount Accumulated amortization Foreign currency exchange rate fluctuations Net carrying amount Useful life (years) (In thousands, except for years) Customer relationships $ 69,520 $ (10,317 ) $ (355 ) $ 58,848 5 - 30 Acquired technology 30,991 (5,534 ) 14 25,471 3 - 20 Trade names 8,069 (2,289 ) (6 ) 5,774 1 - 12 Patents 1,986 (342 ) — 1,644 2 - 20 Backlog 424 (105 ) (14 ) 305 1.7 Total intangibles assets, net $ 110,990 $ (18,587 ) $ (361 ) $ 92,042 The carrying amounts of intangibles as of December 31, 2014 were as follows: December 31, 2014 Gross carrying amount Accumulated amortization Foreign currency exchange rate fluctuations Net carrying amount Useful life (years) Customer relationships $ 60,150 $ (7,596 ) $ (323 ) $ 52,231 5 - 30 Acquired technology 27,580 (4,068 ) — 23,512 3 - 20 Trade names 7,110 (1,559 ) (17 ) 5,534 3 - 12 Patents 1,655 (265 ) — 1,390 2 - 20 Total intangibles assets, net $ 96,495 $ (13,488 ) $ (340 ) $ 82,667
Future Amortization Expense for Intangible Assets	The estimated future amortization expenses for intangible assets are as follows: September 30, Year ended December 31, (In thousands) Remaining three months of 2015 $ 1,919 2016 6,849 2017 6,034 2018 5,546 2019 5,262 Thereafter 66,432 Total $ 92,042

Deferred Gross Profit (Tables)

Deferred Gross Profit (Tables)	9 Months Ended
	Sep. 30, 2015
Revenue Recognition [Abstract]
Schedule of Deferred Gross Profit	Deferred gross profit consists of the following: September 30, December 31, (In thousands) Sales of medication and supply dispensing systems including packaging equipment (1) $ 44,158 $ 36,947 Less: cost of revenues, excluding installation costs (16,979 ) (8,389 ) Total deferred gross profit $ 27,179 $ 28,558 _________________________________________________ (1) Delivered and invoiced, pending installation.

Commitments (Tables)

Commitments (Tables)	9 Months Ended
	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Minimum Future Payments on Non-Cancelable Operating Leases	At September 30, 2015, future minimum lease payments under such operating leases were as follows: September 30, (In thousands) Remaining three months of 2015 $ 1,751 2016 6,526 2017 5,885 2018 5,490 2019 5,481 Thereafter 15,216 Total minimum future lease payments $ 40,349

Stock Repurchases (Tables)

Stock Repurchases (Tables)	9 Months Ended
	Sep. 30, 2015
Equity [Abstract]
Summary of Stock Repurchases	The following table summarizes our stock repurchases: September 30, December 31, (In thousands, except per share data) Total number of shares repurchased 1,424 884 Dollar amount of shares repurchased $ 50,020 $ 24,091 Average price paid per share $ 35.13 $ 27.24

Employee Benefits and Share-B32

Employee Benefits and Share-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-Based Compensation Expense Recognized in Consolidate Statements of Income	The following table sets forth the total share-based compensation expense recognized in our Condensed Consolidated Statements of Operations: Three months ended Nine months ended September 30, September 30, September 30, September 30, (In thousands) Cost of product and service revenues $ 581 $ 441 $ 1,630 $ 973 Research and development 587 407 1,472 1,156 Selling, general and administrative 2,798 2,313 8,165 6,481 Total share-based compensation expense $ 3,966 $ 3,161 $ 11,267 $ 8,610
Estimate of Fair Value of Share-Based Awards, Employee Stock Purchase Plan	The following weighted average assumptions are used to value share options and Employee Stock Purchase Plan ("ESPP") shares issued pursuant to our equity incentive plans for the three and nine months ended September 30, 2015 and September 30, 2014 : Three months ended Nine months ended September 30, September 30, September 30, September 30, (In thousands, except percentages) Stock Option Plans Expected life, years 5.04 4.81 5.04 4.80 Expected volatility, % 29.3 % 34.1 % 31.1 % 35.1 % Risk free interest rate, % 1.73 % 1.70 % 1.63 % 1.56 % Estimated forfeiture rate % 2.5 % 2.5 % 2.5 % 2.5 % Dividend yield, % — % — % — % — % Three months ended Nine months ended September 30, September 30, September 30, September 30, (In thousands, except percentages) Employee Stock Purchase Plan Expected life, years 0.5-2.0 0.5-2.0 0.5-2.0 0.5-2.0 Expected volatility, % 25.79-34.36% 29.56-39.69% 25.79-37.53% 29.56-42.16% Risk free interest rate, % 0.12-0.79% 0.03-0.53% 0.03-0.79% 0.03-0.53% Estimated forfeiture rate % — % — % — % — % Dividend yield, % — % — % — % — %
Estimate of Fair Value of Share-Based Awards, Share Options	The following weighted average assumptions are used to value share options and Employee Stock Purchase Plan ("ESPP") shares issued pursuant to our equity incentive plans for the three and nine months ended September 30, 2015 and September 30, 2014 : Three months ended Nine months ended September 30, September 30, September 30, September 30, (In thousands, except percentages) Stock Option Plans Expected life, years 5.04 4.81 5.04 4.80 Expected volatility, % 29.3 % 34.1 % 31.1 % 35.1 % Risk free interest rate, % 1.73 % 1.70 % 1.63 % 1.56 % Estimated forfeiture rate % 2.5 % 2.5 % 2.5 % 2.5 % Dividend yield, % — % — % — % — % Three months ended Nine months ended September 30, September 30, September 30, September 30, (In thousands, except percentages) Employee Stock Purchase Plan Expected life, years 0.5-2.0 0.5-2.0 0.5-2.0 0.5-2.0 Expected volatility, % 25.79-34.36% 29.56-39.69% 25.79-37.53% 29.56-42.16% Risk free interest rate, % 0.12-0.79% 0.03-0.53% 0.03-0.79% 0.03-0.53% Estimated forfeiture rate % — % — % — % — % Dividend yield, % — % — % — % — %
Stock Option Activity under the Equity Incentive Plans	The following table summarizes the stock option activity under the Company’s equity incentive plans during the nine months ended September 30, 2015 : Number of Shares Weighted-Average Exercise Price Weighted-Average Remaining Years Aggregate Intrinsic Value (1) (In thousands, except per share data) Stock Options Outstanding at December 31, 2014 2,672 $ 19.02 6.5 Granted 322 34.90 Exercised (494 ) 15.90 Expired (2 ) 15.72 Forfeited (81 ) 23.82 Outstanding at September 30, 2015 2,417 $ 21.61 6.5 $ 24,341 Exercisable at September 30, 2015 1,368 $ 16.73 4.8 $ 19,660 Vested and expected to vest at September 30, 2015 and thereafter 2,390 $ 21.50 6.4 $ 24,293 _________________________________________________ (1) Intrinsic value is calculated as the difference between the market value or closing price of our common stock as of the last trading day of the period as reported by the NASDAQ Global Select Market, and the exercise price of the option.
Restricted Stock Units Activity under the Stock Option Activity under the Equity Incentive Plans	Restricted stock activity under the Company’s equity incentive plans in the nine months ended September 30, 2015 is as follows: Number of Shares Weighted-Average Grant Date Fair Value Weighted-Average Remaining Years Aggregate Intrinsic Value (In thousands, except per share data) Restricted Stock Units (RSUs) Outstanding at December 31, 2014 399 $ 24.00 1.5 Granted 131 34.72 Vested (99 ) 21.51 Forfeited (29 ) 23.79 Outstanding and unvested at September 30, 2015 402 $ 28.10 1.3 $ 12,503 Expected to vest after September 30, 2015 392 1.2 $ 12,181
Restricted Stock Units Award under the Stock Option Activity under the Equity Incentive Plans	Number of Shares Weighted-Average Grant Date Fair Value (In thousands, except per share data) Restricted Stock Awards (RSAs) Outstanding at December 31, 2014 36 $ 26.47 Granted 37 36.05 Vested (41 ) 26.47 Forfeited (1 ) 27.65 Outstanding and unvested at September 30, 2015 31 $ 35.95
Performance Shares Restricted Stock Activity under the Stock Option Activity under the Equity Incentive Plans	Performance-based restricted stock activity under our equity incentive plans in the nine months ended September 30, 2015 is as follows: Number of Shares Weighted-Average Grant Date Fair Value Per Unit (In thousands, except per share data) Performance-based Restricted Stock Units (PSUs) Outstanding at December 31, 2014 233 $ 17.96 Granted 60 29.56 Vested (70 ) 18.91 Forfeited (27 ) 14.69 Outstanding and unvested at September 30, 2015 196 $ 21.63
Shares Reserved for Future Issuance under the Stock Option Activity under the Equity Incentive Plans	We had the following ordinary shares reserved for future issuance under our equity incentive plans as of June 30, 2015: Number of Shares (In thousands) Share options outstanding 2,417 Restricted share awards outstanding 629 Shares authorized for future issuance 4,402 ESPP shares available for future issuance 3,251 Total shares reserved for future issuance as of September 30, 2015 10,699

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended
	Sep. 30, 2015
Segment Reporting [Abstract]
Financial Performance of Reporting Segments	The following table summarizes the financial performance of our reportable segments, including a reconciliation of income from segment operations to income from total operations: Three Months Ended September 30, 2015 September 30, 2014 Automation and Analytics Medication Adherence Total Automation and Analytics Medication Adherence Total (In thousands) Revenues $ 102,967 $ 22,267 $ 125,234 $ 89,547 $ 22,996 $ 112,543 Cost of revenues 45,668 15,863 61,531 38,412 14,585 52,997 Gross profit 57,299 6,404 63,703 51,135 8,411 59,546 Operating expenses 30,628 6,070 36,698 27,420 4,822 32,242 Income from segment operations $ 26,671 $ 334 $ 27,005 $ 23,715 $ 3,589 $ 27,304 Corporate costs 13,146 13,707 Income from operations $ 13,859 $ 13,597 Nine Months Ended September 30, 2015 September 30, 2014 Automation and Analytics Medication Adherence Total Automation and Analytics Medication Adherence Total (In thousands) Revenues $ 284,447 $ 69,796 $ 354,243 $ 255,748 $ 63,611 $ 319,359 Cost of revenues 123,923 47,470 171,393 109,344 39,934 149,278 Gross profit 160,524 22,326 182,850 146,404 23,677 170,081 Operating expenses 85,195 18,321 103,516 78,566 14,273 92,839 Income from segment operations $ 75,329 $ 4,005 $ 79,334 $ 67,838 $ 9,404 $ 77,242 Corporate costs 42,672 41,133 Income from operations $ 36,662 $ 36,109 _________________________________________________

Organization and Summary of S34

Organization and Summary of Significant Accounting Policies - (Details)	9 Months Ended
	Sep. 30, 2015	Apr. 30, 2015
Business Acquisition [Line Items]
Period of completed acquisitions	2 years
Avantec [Member]
Business Acquisition [Line Items]
Percentage of interest acquired		85.00%

Net Income Per Share - (Basic

Net Income Per Share - (Basic and Diluted Net Income Per Share) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Earnings Per Share [Abstract]
Net income	$ 8,036	$ 7,300	$ 23,105	$ 21,282
Weighted-average shares outstanding — basic (in shares)	35,806	35,994	35,983	35,634
Dilutive effect of employee stock plans (in shares)	807	838	887	983
Weighted-average shares outstanding — diluted (in shares)	36,613	36,832	36,870	36,617
Net income per share — basic (in dollars per share)	$ 0.22	$ 0.20	$ 0.64	$ 0.60
Net income per share — diluted (in dollars per share)	$ 0.22	$ 0.20	$ 0.63	$ 0.58
Anti-dilutive weighted-average shares related to stock award plans (in shares)	478	427	380	364

Cash and Cash Equivalents and36

Cash and Cash Equivalents and Fair Value of Financial Instruments - Assets Measured at Fair Value On A Recurring Basis (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds	$ 40,108	$ 64,577
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds	40,108	64,577
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash	17,649	61,311
Money market funds	40,108	64,577
Total cash and cash equivalents	$ 57,757	$ 125,888

Cash and Cash Equivalents and37

Cash and Cash Equivalents and Fair Value of Financial Instruments - Schedule of Financial Assets Measured At Fair Value (Details) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds	$ 40,108,000	$ 64,577,000
Derivative contracts	17,000
Total financial assets	40,125,000	64,577,000
Total financial Liabilities	5,572,000	0
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds	40,108,000	64,577,000
Derivative contracts	0
Total financial assets	40,108,000	64,577,000
Total financial Liabilities	0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds	0	0
Derivative contracts	17,000
Total financial assets	17,000	$ 0
Total financial Liabilities	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds	0
Derivative contracts	0
Total financial assets	0
Total financial Liabilities	5,572,000
Contingent Consideration Liability
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial Liabilities	5,572,000
Contingent Consideration Liability | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial Liabilities	0
Contingent Consideration Liability | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial Liabilities	0
Contingent Consideration Liability | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial Liabilities	$ 5,572,000

Cash and Cash Equivalents and38

Cash and Cash Equivalents and Fair Value of Financial Instruments - Foreign Currency Risk Management (Details) - Foreign Exchange Forward [Member] - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Derivatives, Fair Value [Line Items]
Derivative, notional amount	$ 1,800,000
Fair Value, Inputs, Level 2 [Member]
Derivatives, Fair Value [Line Items]
Aggregate fair value of outstanding derivative	$ 100,000	$ 0

Balance Sheet Components (Detai

Balance Sheet Components (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Inventories:
Raw materials	$ 11,027	$ 8,254
Work in process	2,238	64
Finished goods	36,195	23,236
Total inventories	49,460	31,554
Property and equipment:
Equipment	44,448	42,829
Furniture and fixtures	5,903	5,689
Leasehold improvements	9,064	8,701
Purchased software	29,770	28,920
Construction in progress	4,902	1,538
Property and equipment, gross	94,087	87,677
Accumulated depreciation and amortization	(60,061)	(51,499)
Total property and equipment, net	34,026	36,178
Other long term assets:
Capitalized software, net	24,838	19,643
Other assets	2,133	3,630
Total other long term assets, net	26,971	23,273
Accrued liabilities:
Rebates and lease buyouts	4,603	6,512
Advance payments from customers	7,567	4,834
Group purchasing organization fees	3,437	3,475
Taxes payable	3,574	2,181
Other accrued liabilities	10,201	2,297
Total accrued liabilities	$ 29,382	$ 19,299

Net Investment in Sales-Type 40

Net Investment in Sales-Type Leases - Long Term Net Investment in Sales Type Leases (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Capital Leased Assets [Line Items]
Net minimum lease payments to be received	$ 20,731	$ 17,616
Less: unearned interest income portion	(1,000)	(1,131)
Net investment in sales-type leases	19,731	16,485
Less: short-term portion	(6,174)	(5,637)
Long-term net investment in sales-type leases	13,557	10,848
Collective allowance for credit losses	$ 100	$ 200
Minimum [Member]
Capital Leased Assets [Line Items]
Terms of sales-type leases (generally up to five years in length)	1 year
Maximum [Member]
Capital Leased Assets [Line Items]
Terms of sales-type leases (generally up to five years in length)	5 years

Net Investment in Sales-Type 41

Net Investment in Sales-Type Leases - Capital Leases, Future Minimum Payments Receivable (Details) $ in Thousands	Sep. 30, 2015USD ($)
Leases [Abstract]
Remaining three months of 2015	$ 1,774
2,016	6,454
2,017	5,428
2,018	3,808
2,019	2,188
Thereafter	1,079
Total	$ 20,731

Business Acquisitions - Additio

Business Acquisitions - Additional Information (Details) - USD ($) $ in Thousands	Apr. 30, 2015	Apr. 21, 2015	Sep. 30, 2015	Jun. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Apr. 29, 2014
Business Acquisition [Line Items]
Difference between fair value and carrying value as a gain			$ 0		$ 0	$ 3,443	$ 0
Avantec [Member]
Business Acquisition [Line Items]
Business acquisition, amount withheld for idemnification	$ 1,800
Percentage of minority interest								15.00%
Carrying book value of previous equity interest	$ 1,300
Fair value of equity investment				$ 4,700
Difference between fair value and carrying value as a gain				3,400
Mach4 [Member]
Business Acquisition [Line Items]
Payment to acquire business, amount in cash after adjustments		$ 17,200
Amount placed in escrow fund for business acquisition		$ 2,700
Period after closing date to settle indemnification and other claims		18 months
Mach4 [Member] | Developed technology [Member] | Income Approach Valuation Technique [Member]
Business Acquisition [Line Items]
Discount rate		17.50%
Royalty rate		5.00%
Mach4 [Member] | Trade names [Member] | Income Approach Valuation Technique [Member]
Business Acquisition [Line Items]
Royalty rate		2.00%
Mach4 [Member] | Minimum [Member] | Developed technology [Member] | Income Approach Valuation Technique [Member]
Business Acquisition [Line Items]
Discount rate		1.50%
Avantec [Member]
Business Acquisition [Line Items]
Period after closing date to settle indemnification and other claims	18 months
Percentage of interest acquired	85.00%
Payment to acquire business, in cash	$ 12,000
Business acquisition, potential earn-out payment	$ 5,600
Difference between fair value and carrying value as a gain				$ 3,400
Avantec [Member] | Trade names [Member] | Income Approach Valuation Technique [Member]
Business Acquisition [Line Items]
Royalty rate	1.00%
Avantec [Member] | Payable After December 31, 2015 [Member]
Business Acquisition [Line Items]
Business acquisition, potential earn-out payment	$ 3,000
Avantec [Member] | Payable After December 31, 2016 [Member]
Business Acquisition [Line Items]
Business acquisition, potential earn-out payment	$ 3,000

Business Acquisitions - Total P

Business Acquisitions - Total Purchase Price and Identifiable Intangible Assets (Details) - USD ($) $ in Thousands	Apr. 30, 2015	Apr. 30, 2015	Apr. 21, 2015	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Total Purchase Price
Cash	$ 3,789	$ 3,789
Accounts receivable	7,350	7,350
Inventory	5,008	5,008
Deferred tax assets and other current assets	457	457
Total current assets	16,604	16,604
Property and equipment	463	463
Intangibles	14,051	14,051
Goodwill	26,145	26,145		$ 148,727		$ 122,720
Other non-current assets	52	52
Total assets	57,315	57,315
Current liabilities	7,809	7,809
Non-current deferred tax liabilities	3,833	3,833
Deferred service revenue and gross profit	3,242	3,242
Other non-current liabilities	1,056	1,056
Total purchase price	41,375	41,375
Total purchase price, net of cash received	37,586			$ 25,455	$ 19,749
Mach4 [Member]
Total Purchase Price
Cash			$ 397
Accounts receivable			3,743
Inventory			3,580
Deferred tax assets and other current assets			368
Total current assets			8,088
Property and equipment			463
Intangibles			7,710
Goodwill			10,539
Other non-current assets			52
Total assets			26,852
Current liabilities			3,684
Non-current deferred tax liabilities			2,564
Deferred service revenue and gross profit			2,314
Other non-current liabilities			1,056
Total purchase price			17,234
Total purchase price, net of cash received			16,837
Identifiable Intangible Assets
Fair value of identifiable intangible assets purchased			7,710
Avantec [Member]
Total Purchase Price
Cash	3,392	3,392
Accounts receivable	3,607	3,607
Inventory	1,428	1,428
Deferred tax assets and other current assets	89	89
Total current assets	8,516	8,516
Property and equipment	0	0
Intangibles	6,341	6,341
Goodwill	15,606	15,606
Other non-current assets	0	0
Total assets	30,463	30,463
Current liabilities	4,125	4,125
Non-current deferred tax liabilities	1,269	1,269
Deferred service revenue and gross profit	928	928
Other non-current liabilities	0	0
Total purchase price	$ 24,141	24,141
Total purchase price, net of cash received		20,749
Identifiable Intangible Assets
Fair value of identifiable intangible assets purchased		6,341
Developed technology [Member] | Mach4 [Member]
Identifiable Intangible Assets
Fair value of identifiable intangible assets purchased			$ 3,290
Weighted average useful life (in years)			8 years
Trade names [Member] | Mach4 [Member]
Identifiable Intangible Assets
Fair value of identifiable intangible assets purchased			$ 850
Weighted average useful life (in years)			6 years
Trade names [Member] | Avantec [Member]
Identifiable Intangible Assets
Fair value of identifiable intangible assets purchased		$ 92
Weighted average useful life (in years)		2 years
Customer relationships [Member] | Mach4 [Member]
Identifiable Intangible Assets
Fair value of identifiable intangible assets purchased			$ 3,570
Customer relationships [Member] | Avantec [Member]
Identifiable Intangible Assets
Fair value of identifiable intangible assets purchased		$ 5,834
Weighted average useful life (in years)		12 years
Backlog [Member] | Avantec [Member]
Identifiable Intangible Assets
Fair value of identifiable intangible assets purchased		$ 415
Weighted average useful life (in years)		2 years
Minimum [Member] | Customer relationships [Member] | Mach4 [Member]
Identifiable Intangible Assets
Weighted average useful life (in years)			11 years
Maximum [Member] | Customer relationships [Member] | Mach4 [Member]
Identifiable Intangible Assets
Weighted average useful life (in years)			12 years

Business Acquisitions - Pro For

Business Acquisitions - Pro Forma Information (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Business Combinations [Abstract]
Pro forma net revenues	$ 361,217	$ 340,915
Pro forma net income	$ 23,742	$ 22,511
Pro forma net income (loss) per share basic (in dollars per share)	$ 0.66	$ 0.63
Pro forma net income (loss) per share diluted (in dollars per share)	$ 0.64	$ 0.61

Goodwill and Intangible Asset45

Goodwill and Intangible Assets - Carrying Amount of Goodwill (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2015USD ($)
Goodwill [Roll Forward]
Net balance as of December 31, 2014	$ 122,720
Foreign currency exchange rate fluctuations	(138)
Net balance as of September 30, 2015	148,727
Automation and Analytics [Member]
Goodwill [Roll Forward]
Net balance as of December 31, 2014	28,543
Foreign currency exchange rate fluctuations	194
Net balance as of September 30, 2015	54,882
Medication Adherence [Member]
Goodwill [Roll Forward]
Net balance as of December 31, 2014	94,177
Foreign currency exchange rate fluctuations	(332)
Net balance as of September 30, 2015	93,845
Mach4 [Member]
Goodwill [Roll Forward]
Goodwill acquired	10,539
Mach4 [Member] | Automation and Analytics [Member]
Goodwill [Roll Forward]
Goodwill acquired	10,539
Mach4 [Member] | Medication Adherence [Member]
Goodwill [Roll Forward]
Goodwill acquired	0
Avantec [Member]
Goodwill [Roll Forward]
Goodwill acquired	15,606
Avantec [Member] | Automation and Analytics [Member]
Goodwill [Roll Forward]
Goodwill acquired	15,606
Avantec [Member] | Medication Adherence [Member]
Goodwill [Roll Forward]
Goodwill acquired	$ 0

Goodwill and Intangible Asset46

Goodwill and Intangible Assets - Intangible Assets, Net (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Acquired Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross Carrying Amount	$ 110,990	$ 96,495
Intangible Assets, Accumulated Amortization	(18,587)	(13,488)
Intangible Assets, Foreign Currency Exchange Rate Fluctuations	(361)	(340)
Total Intangibles Assets, Net Carrying Amount	92,042	82,667
Customer relationships [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross Carrying Amount	69,520	60,150
Intangible Assets, Accumulated Amortization	(10,317)	(7,596)
Intangible Assets, Foreign Currency Exchange Rate Fluctuations	(355)	(323)
Total Intangibles Assets, Net Carrying Amount	58,848	52,231
Acquired technology [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross Carrying Amount	30,991	27,580
Intangible Assets, Accumulated Amortization	(5,534)	(4,068)
Intangible Assets, Foreign Currency Exchange Rate Fluctuations	14	0
Total Intangibles Assets, Net Carrying Amount	25,471	23,512
Trade names [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross Carrying Amount	8,069	7,110
Intangible Assets, Accumulated Amortization	(2,289)	(1,559)
Intangible Assets, Foreign Currency Exchange Rate Fluctuations	(6)	(17)
Total Intangibles Assets, Net Carrying Amount	5,774	5,534
Patents [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross Carrying Amount	1,986	1,655
Intangible Assets, Accumulated Amortization	(342)	(265)
Intangible Assets, Foreign Currency Exchange Rate Fluctuations	0	0
Total Intangibles Assets, Net Carrying Amount	1,644	$ 1,390
Backlog [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross Carrying Amount	424
Intangible Assets, Accumulated Amortization	(105)
Intangible Assets, Foreign Currency Exchange Rate Fluctuations	(14)
Total Intangibles Assets, Net Carrying Amount	$ 305
Useful Life (Years)	1 year 8 months 12 days
Maximum [Member] | Customer relationships [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Useful Life (Years)	30 years	30 years
Maximum [Member] | Acquired technology [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Useful Life (Years)	20 years	20 years
Maximum [Member] | Trade names [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Useful Life (Years)	12 years	12 years
Maximum [Member] | Patents [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Useful Life (Years)	20 years	20 years
Minimum [Member] | Customer relationships [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Useful Life (Years)	5 years	5 years
Minimum [Member] | Acquired technology [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Useful Life (Years)	3 years	3 years
Minimum [Member] | Trade names [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Useful Life (Years)	1 year	3 years
Minimum [Member] | Patents [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Useful Life (Years)	2 years	2 years

Goodwill and Intangible Asset47

Goodwill and Intangible Assets - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense of intangible assets	$ 2	$ 1.2	$ 5.1	$ 3.3

Goodwill and Intangible Asset48

Goodwill and Intangible Assets - Future Amortization Expense for Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Remaining three months of 2015	$ 1,919
2,016	6,849
2,017	6,034
2,018	5,546
2,019	5,262
Thereafter	66,432
Total Intangibles Assets, Net Carrying Amount	$ 92,042	$ 82,667

Deferred Gross Profit - Additi

Deferred Gross Profit - Additional Information (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Total deferred gross profit	$ 27,179	$ 28,558
Products with Installation Services [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Sales of medication and supply dispensing systems including packaging equipment	44,158	36,947
Less: cost of revenues, excluding installation costs	(16,979)	(8,389)
Total deferred gross profit	$ 27,179	$ 28,558

Commitments - Minimum Future P

Commitments - Minimum Future Payments on Non-Cancelable Operating Leases (Details) $ in Thousands	Sep. 30, 2015USD ($)
Commitments and Contingencies Disclosure [Abstract]
Remaining three months of 2015	$ 1,751
2,016	6,526
2,017	5,885
2,018	5,490
2,019	5,481
Thereafter	15,216
Total minimum future lease payments	40,349
Purchase obligation due within the next twelve months	$ 28,800

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended			9 Months Ended		12 Months Ended
	Sep. 30, 2015	Jun. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Apr. 30, 2015	Apr. 29, 2014
Income Tax Disclosure [Abstract]
Effective tax rate				39.30%	40.50%
Statutory income tax rate				35.00%		35.00%
Business Acquisition [Line Items]
Gain on business combination	$ 0		$ 0	$ 3,443	$ 0
Gross unrecognized tax benefits	$ 7,100			$ 7,100		$ 5,900
Avantec [Member]
Business Acquisition [Line Items]
Gain on business combination		$ 3,400
Percentage of minority interest								15.00%
Avantec [Member]
Business Acquisition [Line Items]
Gain on business combination		$ 3,400
Percentage of interest acquired							85.00%

Stock Repurchases - Additional

Stock Repurchases - Additional Information (Details) - USD ($) $ / shares in Units, shares in Thousands	6 Months Ended	9 Months Ended	11 Months Ended	12 Months Ended	29 Months Ended
	Jun. 30, 2015	Sep. 30, 2015	Sep. 30, 2015	Dec. 31, 2014	Dec. 31, 2014	Nov. 30, 2014	Aug. 31, 2012
Equity, Class of Treasury Stock [Line Items]
Stock repurchases program, remaining authorized repurchase amount		$ 4,900,000	$ 4,900,000
Total number of shares repurchased (in shares)		1,424		884
Dollar amount of shares repurchased		$ 50,020,000		$ 24,091,000
Average price paid per share (in dollars per share)		$ 35.13		$ 27.24
August 2012 Stock Repurchase Program [Member]
Equity, Class of Treasury Stock [Line Items]
Stock repurchases program, authorized amount							$ 50,000,000
Stock repurchases program, amount repurchased	$ 4,900,000				$ 45,100,000
November 2014 Stock Repurchase Program [Member]
Equity, Class of Treasury Stock [Line Items]
Stock repurchases program, authorized amount						$ 50,000,000
Stock repurchases program, amount repurchased			$ 45,100,000

Employee Benefits and Share-B53

Employee Benefits and Share-Based Compensation - Shared-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	$ 3,966	$ 3,161	$ 11,267	$ 8,610
Cost of product and service revenues [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	581	441	1,630	973
Research and development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	587	407	1,472	1,156
Selling, general and administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	$ 2,798	$ 2,313	$ 8,165	$ 6,481

Employee Benefits and Share-B54

Employee Benefits and Share-Based Compensation - Valuation of Share Based Awards, Table (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life, years	5 years 15 days	4 years 9 months 22 days	5 years 15 days	4 years 9 months 20 days
Expected volatility, %	29.30%	34.10%	31.10%	35.10%
Risk free interest rate, %	1.73%	1.70%	1.63%	1.56%
Estimated forfeiture rate %	2.50%	2.50%	2.50%	2.50%
Dividend yield, %	0.00%	0.00%	0.00%	0.00%
Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility, %, Min	25.79%	29.56%	25.79%	29.56%
Expected volatility, %, Max	34.36%	39.69%	37.53%	42.16%
Risk free interest rate, %, Min	0.12%	0.03%	0.03%	0.03%
Risk free interest rate, %, Max	0.79%	0.53%	0.79%	0.53%
Estimated forfeiture rate %	0.00%	0.00%	0.00%	0.00%
Dividend yield, %	0.00%	0.00%	0.00%	0.00%
Minimum [Member] | Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life, years	6 months	6 months	6 months	6 months
Maximum [Member] | Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life, years	2 years	2 years	2 years	2 years

Employee Benefits and Share-B55

Employee Benefits and Share-Based Compensation - Stock Option Activity (Details) - 2009 Plan [Member] - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Number of Shares
Outstanding at December 31, 2014 (in shares)			2,672
Granted (in shares)			322
Exercised (in shares)			(494)
Expired (in shares)			(2)
Forfeited (in shares)			(81)
Outstanding at September 30, 2015 (in shares)	2,417		2,417		2,672
Exercisable at September 30, 2015 (in shares)	1,368		1,368
Vested and expected to vest at September 30, 2015 (in shares)	2,390		2,390
Weighted Average Exercise Price
Outstanding at December 31, 2014 (in dollars per share)			$ 19.02
Granted (in dollars per share)			34.90
Exercised (in dollars per share)			15.90
Expired (in dollars per share)			15.72
Forfeited (in dollars per share)			23.82
Outstanding at September 30, 2015 (in dollars per share)	$ 21.61		21.61		$ 19.02
Exercisable at September 30, 2015 (in dollars per share)	16.73		16.73
Vested and expected to vest at September 30, 2015 (in dollars per share)	$ 21.50		$ 21.50
Weighted-average remaining years, outstanding (in years)			6 years 6 months		6 years 6 months
Weighted-average remaining years, exercisable at December 31, 2014 (in years)			4 years 9 months 30 days
Weighted-average remaining years, vested and expected to vest at September 30, 2015 (in years)			6 years 4 months 24 days
Aggregate Intrinsic Value, outstanding at September 30, 2015	$ 24,341		$ 24,341
Aggregate Intrinsic Value, exercisable at September 30, 2015	19,660		19,660
Aggregate Intrinsic Value, vested and expected to vest at September 30, 2015	$ 24,293		$ 24,293
Employee Stock Option [Member]
Weighted Average Exercise Price
Weighted-average fair value (in dollars per share)	$ 10.51	$ 8.51	$ 10.57	$ 8.78
Intrinsic value of options exercised	$ 3,100	$ 2,500	$ 9,700	$ 10,400
Unrecognized compensation cost of unvested stock options	$ 9,000		$ 9,000
Weighted average period of compensation cost recognized			2 years 8 months 12 days

Employee Benefits and Share-B56

Employee Benefits and Share-Based Compensation - Restricted Stock Activity (Details) - 2009 Plan [Member] - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Restricted Stock Units (RSUs) [Member]
Number of Shares
Outstanding at December 31, 2014 (in shares)	399
Granted (in shares)	131
Vested (in shares)	(99)
Forfeited (in shares)	(29)
Outstanding and unvested at September 30, 2015 (in shares)	402		399
Expected to vest at September 30, 2015 (in shares)	392
Weighted-Average Grant Date Fair Value
Outstanding and unvested (in dollars per share)	$ 24
Granted (in dollars per share)	34.72	$ 25.16
Vested (in dollars per share)	21.51
Forfeited (in dollars per share)	23.79
Outstanding and unvested (in dollars per share)	$ 28.10		$ 24
Weighted-average remaining years, expected to vest at September 30, 2015 (in years)	1 year 2 months 12 days
Weighted-average remaining years, outstanding and unvested (in years)	1 year 3 months 18 days		1 year 6 months
Aggregate Intrinsic Value
Outstanding and unvested at September 30, 2015	$ 12,503
Expected to vest after September 30, 2015	12,181
Unrecognized compensation expense	$ 9,300
Weighted average period of compensation cost recognized	2 years 4 months 24 days
Restricted Stock Awards [Member]
Number of Shares
Outstanding at December 31, 2014 (in shares)	36
Granted (in shares)	37
Vested (in shares)	(41)
Forfeited (in shares)	(1)
Outstanding and unvested at September 30, 2015 (in shares)	31		36
Weighted-Average Grant Date Fair Value
Outstanding and unvested (in dollars per share)	$ 26.47
Granted (in dollars per share)	36.05
Vested (in dollars per share)	26.47
Forfeited (in dollars per share)	27.65
Outstanding and unvested (in dollars per share)	$ 35.95		$ 26.47
Aggregate Intrinsic Value
Unrecognized compensation expense	$ 700
Weighted average period of compensation cost recognized	8 months 24 days

Employee Benefits and Share-B57

Employee Benefits and Share-Based Compensation - Performance Based Restricted Stock Unit Activity (Details) - 2009 Plan [Member] - Performance Shares [Member] - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Number of Shares
Outstanding at December 31, 2014 (in shares)	233
Granted (in shares)	60
Vested (in shares)	(70)
Canceled (in shares)	(27)
Outstanding and unvested at September 30, 2015 (in shares)	196
Weighted-Average Grant Date Fair Value Per Share
Outstanding and unvested (in dollars per share)	$ 17.96
Granted (in dollars per share)	29.56	$ 14.36
Vested (in dollars per share)	18.91
Canceled (in dollars per share)	14.69
Outstanding and unvested (in dollars per share)	$ 21.63
Fair value of restricted stock units	$ 2.6	$ 2.1
Unrecognized compensation cost	$ 2
Weighted average period of compensation cost recognized	1 year 1 month 24 days

Employee Benefits and Share-B58

Employee Benefits and Share-Based Compensation - Employee Stock Purchase Plan (ESPP) Activity (Details) - 1997 Employee Stock Purchase Plan [Member] - Employee Stock Purchase Plan [Member] $ in Millions	9 Months Ended
	Sep. 30, 2015USD ($)
Share-Based Arrangements with Employees and Nonemployees [Line Items]
Unrecognized compensation cost	$ 2.1
Weighted average period of compensation cost recognized	1 month 6 days

Employee Benefits and Share-B59

Employee Benefits and Share-Based Compensation - Summary of Shares Reserved for Future Issuance Under Equity Incentive Plans (Details) shares in Thousands	Sep. 30, 2015shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for future issuance as of September 30, 2015	10,699
Share options outstanding [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for future issuance as of September 30, 2015	2,417
Restricted shares award outstanding [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for future issuance as of September 30, 2015	629
Shares authorized for future issuance [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for future issuance as of September 30, 2015	4,402
ESPP shares available for future issuance [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for future issuance as of September 30, 2015	3,251

Segment Information - Addition

Segment Information - Additional Information (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2015customer	Sep. 30, 2014customer	Sep. 30, 2015segmentcustomer	Sep. 30, 2014customer
Segment Reporting [Abstract]
Period of completed acquisitions			2 years
Number of segments			2
Number of reportable segments			2
Number of significant customers that accounted for more than 10% of accounts receivables | customer	0	0	0	0

Segment Information - Financia

Segment Information - Financial Performance of Reporting Segments (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Segment Reporting Information [Line Items]
Revenues	$ 125,234	$ 112,543	$ 354,243	$ 319,359
Cost of revenues	61,531	52,997	171,393	149,278
Gross profit	63,703	59,546	182,850	170,081
Operating expenses	49,844	45,949	146,188	133,972
Income from operations	13,859	13,597	36,662	36,109
Operating segments [Member]
Segment Reporting Information [Line Items]
Revenues	125,234	112,543	354,243	319,359
Cost of revenues	61,531	52,997	171,393	149,278
Gross profit	63,703	59,546	182,850	170,081
Operating expenses	36,698	32,242	103,516	92,839
Income from operations	27,005	27,304	79,334	77,242
Operating segments [Member] | Automation and Analytics [Member]
Segment Reporting Information [Line Items]
Revenues	102,967	89,547	284,447	255,748
Cost of revenues	45,668	38,412	123,923	109,344
Gross profit	57,299	51,135	160,524	146,404
Operating expenses	30,628	27,420	85,195	78,566
Income from operations	26,671	23,715	75,329	67,838
Operating segments [Member] | Medication Adherence [Member]
Segment Reporting Information [Line Items]
Revenues	22,267	22,996	69,796	63,611
Cost of revenues	15,863	14,585	47,470	39,934
Gross profit	6,404	8,411	22,326	23,677
Operating expenses	6,070	4,822	18,321	14,273
Income from operations	334	3,589	4,005	9,404
Corporate cost [Member]
Segment Reporting Information [Line Items]
Operating expenses	$ 13,146	$ 13,707	$ 42,672	$ 41,133

Subsequent Events - (Details)

Subsequent Events - (Details) - Subsequent Event [Member]	Oct. 29, 2015USD ($)
Medium-term Notes [Member]
Subsequent Event [Line Items]
Debt instrument, amount	$ 200,000,000
Secured Debt [Member] | Senior Notes [Member]
Subsequent Event [Line Items]
Debt instrument, amount	300,000,000
Revolving Credit Facility [Member] | Line of Credit [Member]
Subsequent Event [Line Items]
Debt instrument, amount	100,000,000
Aesynt Holding, L.P., Aesynt, Ltd. [Member]
Subsequent Event [Line Items]
Total aggregate consideration, in cash	275,000,000
Aggregate consideration minus indebtedness at close	$ 217,500,000